Bangalore, April 23, 2008: Ranbaxy Laboratories Limited and Orchid Chemicals & Pharmaceuticals Limited have entered into a Business Alliance Agreement involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients. Additionally, this agreement would establish a framework for enhanced future co-operation between the two companies.

 

Speaking on the development, Mr Malvinder Mohan Singh, CEO  & MD,   Ranbaxy, said, "Orchid is a niche player in the global pharmaceutical industry with an impressive track record, particularly in sterile products. We are pleased to enter into this long term strategic alliance with Orchid. The agreement will be mutually beneficial and synergistic, allowing both organizations to leverage each others inherent strengths." 

 

Commenting on the alliance, Mr K. Raghavendra Rao, Managing Director, Orchid, said, "Ranbaxy's global scale and market reach and Orchid's state-of-the-art development and manufacturing capabilities would expand the business of both companies. We believe that this will be a win-win arrangement for both companies.”